Last reviewed · How we verify
Chidamide Combined With Cladribine/Gemcitabine/Busulfan (ChiCGB) With Autologous Stem-Cell Transplantation in Relapsed and Refractory Diffuse Large B Cell Lymphoma
The goal of this clinical research study is to evaluate effectiveness and safety of ChiCGB regimen( chidamide, cladribine, gemcitabine and busulfan). Busulfan are designed to kill cancer cells by binding to DNA (the genetic material of cells), which may cause cancer cells to die. Gemcitabine and cladribine are designed to disrupt the growth of cancer cells, which may cause cancer cells to die. It may help to increase the effect of busulfan on cancer cells by not allowing these cells to repair the DNA damage caused by busulfan. Chidamide is designed to open up the DNA and allow greater access to drugs that bind to DNA, such as cladribine, gemcitabine, busulfan.
Details
| Lead sponsor | Sichuan University |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 93 |
| Start date | 2017-06-12 |
| Completion | 2021-12 |
Conditions
- Lymphoma
Interventions
- Chidamide
- Cladribine
- gemcitabine
- Busulfan
- Autologous hematopoietic stem cell transplantation
Primary outcomes
- Event free survival — 2 years
Countries
China